Compound GW506U78 in refractory hematologic malignancies

Relationship between cellular pharmacokinetics and clinical response

Varsha Gandhi, William Plunkett, Carlos O. Rodriguez, Billie J. Nowak, Min Du, Mary Ayres, David F. Kisor, Beverly S. Mitchell, Joanne Kurtzberg, Michael J. Keating

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Purpose: In vitro investigations with arabinosylguanine (ara-G) demonstrated potent cytatoxicity to T-lymphoblastoid cell lines. The goals of the present study were to evaluate GW506U78, a prodrug of ara-G, against human hematologic malignancies and to determine its pharmacokinetics in plasma and cells. Patients and Methods: During o phase I multicenter trial of GW506U78, 26 patients were treated at M.D. Anderson Cancer Center (MDACC). Daily doses between 20 and 60 mg/kg were administered for 5 days. Parallel plasma and cellular pharmacokinetic studies were conducted. Results: Complete (n = 5) or partial remission (n = 5) was achieved in T-cell acute lymphoblastic leukemia (T-ALL), T-lymphoid blast crisis, T-lymphoma, and B- cell chronic lymphocytic leukemia (B-CLL) (n = 13). In contrast, patients with B-ALL, B-lymphoma, acute myelogenous leukemia (AMI), or T-CLL did not respond. Peak plasma concentrations of GW506U78 and ara-G were dose- dependent. The elimination of GW506U78 (half life [t 1/4 ] = 17 minutes) was faster than the elimination of ara-G (t 1/4 = 3.7 hours). Median peak concentrations of ara-GTP were 23, 42, 85, and 93 μmol/L at 20, 30, 40, and 60 mg/kg, respectively. T-lymphoblasts accumulated significantly (P = .0008) higher peak arabinsyl-guanosine triphosphate (ara-GTP) (median, 140 μmol/L; n = 7) compared with other diagnoses (median, 50 μmol/L; n = 9) and normal mononuclear cells (n = 3). The ara-GTP elimination was slow in all diagnoses (median, > 24 hours). Responders accumulated significantly (P = .0005) higher levels of ara-GTP (median, 157 μmol/L) compared with patients who failed to respond (median, 44 μmol/L). Conclusion: GW506U78 is an effective prodrug and a potent agent for hematologic malignancies with major efficacy in T- cell diseases. The pharmacokinetics of ara-GTP in leukemia cells are strongly correlated with clinical responses to GW506U78.

Original languageEnglish (US)
Pages (from-to)3607-3615
Number of pages9
JournalJournal of Clinical Oncology
Volume16
Issue number11
StatePublished - Nov 1998
Externally publishedYes

Fingerprint

Hematologic Neoplasms
Guanosine Triphosphate
Pharmacokinetics
Prodrugs
Lymphoma
T-Lymphocytes
Blast Crisis
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Plasma Cells
Acute Myeloid Leukemia
Multicenter Studies
Half-Life
nelarabine
Leukemia
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gandhi, V., Plunkett, W., Rodriguez, C. O., Nowak, B. J., Du, M., Ayres, M., ... Keating, M. J. (1998). Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response. Journal of Clinical Oncology, 16(11), 3607-3615.

Compound GW506U78 in refractory hematologic malignancies : Relationship between cellular pharmacokinetics and clinical response. / Gandhi, Varsha; Plunkett, William; Rodriguez, Carlos O.; Nowak, Billie J.; Du, Min; Ayres, Mary; Kisor, David F.; Mitchell, Beverly S.; Kurtzberg, Joanne; Keating, Michael J.

In: Journal of Clinical Oncology, Vol. 16, No. 11, 11.1998, p. 3607-3615.

Research output: Contribution to journalArticle

Gandhi, V, Plunkett, W, Rodriguez, CO, Nowak, BJ, Du, M, Ayres, M, Kisor, DF, Mitchell, BS, Kurtzberg, J & Keating, MJ 1998, 'Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response', Journal of Clinical Oncology, vol. 16, no. 11, pp. 3607-3615.
Gandhi, Varsha ; Plunkett, William ; Rodriguez, Carlos O. ; Nowak, Billie J. ; Du, Min ; Ayres, Mary ; Kisor, David F. ; Mitchell, Beverly S. ; Kurtzberg, Joanne ; Keating, Michael J. / Compound GW506U78 in refractory hematologic malignancies : Relationship between cellular pharmacokinetics and clinical response. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 11. pp. 3607-3615.
@article{2cf272531d8847818df18851bc19f525,
title = "Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response",
abstract = "Purpose: In vitro investigations with arabinosylguanine (ara-G) demonstrated potent cytatoxicity to T-lymphoblastoid cell lines. The goals of the present study were to evaluate GW506U78, a prodrug of ara-G, against human hematologic malignancies and to determine its pharmacokinetics in plasma and cells. Patients and Methods: During o phase I multicenter trial of GW506U78, 26 patients were treated at M.D. Anderson Cancer Center (MDACC). Daily doses between 20 and 60 mg/kg were administered for 5 days. Parallel plasma and cellular pharmacokinetic studies were conducted. Results: Complete (n = 5) or partial remission (n = 5) was achieved in T-cell acute lymphoblastic leukemia (T-ALL), T-lymphoid blast crisis, T-lymphoma, and B- cell chronic lymphocytic leukemia (B-CLL) (n = 13). In contrast, patients with B-ALL, B-lymphoma, acute myelogenous leukemia (AMI), or T-CLL did not respond. Peak plasma concentrations of GW506U78 and ara-G were dose- dependent. The elimination of GW506U78 (half life [t 1/4 ] = 17 minutes) was faster than the elimination of ara-G (t 1/4 = 3.7 hours). Median peak concentrations of ara-GTP were 23, 42, 85, and 93 μmol/L at 20, 30, 40, and 60 mg/kg, respectively. T-lymphoblasts accumulated significantly (P = .0008) higher peak arabinsyl-guanosine triphosphate (ara-GTP) (median, 140 μmol/L; n = 7) compared with other diagnoses (median, 50 μmol/L; n = 9) and normal mononuclear cells (n = 3). The ara-GTP elimination was slow in all diagnoses (median, > 24 hours). Responders accumulated significantly (P = .0005) higher levels of ara-GTP (median, 157 μmol/L) compared with patients who failed to respond (median, 44 μmol/L). Conclusion: GW506U78 is an effective prodrug and a potent agent for hematologic malignancies with major efficacy in T- cell diseases. The pharmacokinetics of ara-GTP in leukemia cells are strongly correlated with clinical responses to GW506U78.",
author = "Varsha Gandhi and William Plunkett and Rodriguez, {Carlos O.} and Nowak, {Billie J.} and Min Du and Mary Ayres and Kisor, {David F.} and Mitchell, {Beverly S.} and Joanne Kurtzberg and Keating, {Michael J.}",
year = "1998",
month = "11",
language = "English (US)",
volume = "16",
pages = "3607--3615",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Compound GW506U78 in refractory hematologic malignancies

T2 - Relationship between cellular pharmacokinetics and clinical response

AU - Gandhi, Varsha

AU - Plunkett, William

AU - Rodriguez, Carlos O.

AU - Nowak, Billie J.

AU - Du, Min

AU - Ayres, Mary

AU - Kisor, David F.

AU - Mitchell, Beverly S.

AU - Kurtzberg, Joanne

AU - Keating, Michael J.

PY - 1998/11

Y1 - 1998/11

N2 - Purpose: In vitro investigations with arabinosylguanine (ara-G) demonstrated potent cytatoxicity to T-lymphoblastoid cell lines. The goals of the present study were to evaluate GW506U78, a prodrug of ara-G, against human hematologic malignancies and to determine its pharmacokinetics in plasma and cells. Patients and Methods: During o phase I multicenter trial of GW506U78, 26 patients were treated at M.D. Anderson Cancer Center (MDACC). Daily doses between 20 and 60 mg/kg were administered for 5 days. Parallel plasma and cellular pharmacokinetic studies were conducted. Results: Complete (n = 5) or partial remission (n = 5) was achieved in T-cell acute lymphoblastic leukemia (T-ALL), T-lymphoid blast crisis, T-lymphoma, and B- cell chronic lymphocytic leukemia (B-CLL) (n = 13). In contrast, patients with B-ALL, B-lymphoma, acute myelogenous leukemia (AMI), or T-CLL did not respond. Peak plasma concentrations of GW506U78 and ara-G were dose- dependent. The elimination of GW506U78 (half life [t 1/4 ] = 17 minutes) was faster than the elimination of ara-G (t 1/4 = 3.7 hours). Median peak concentrations of ara-GTP were 23, 42, 85, and 93 μmol/L at 20, 30, 40, and 60 mg/kg, respectively. T-lymphoblasts accumulated significantly (P = .0008) higher peak arabinsyl-guanosine triphosphate (ara-GTP) (median, 140 μmol/L; n = 7) compared with other diagnoses (median, 50 μmol/L; n = 9) and normal mononuclear cells (n = 3). The ara-GTP elimination was slow in all diagnoses (median, > 24 hours). Responders accumulated significantly (P = .0005) higher levels of ara-GTP (median, 157 μmol/L) compared with patients who failed to respond (median, 44 μmol/L). Conclusion: GW506U78 is an effective prodrug and a potent agent for hematologic malignancies with major efficacy in T- cell diseases. The pharmacokinetics of ara-GTP in leukemia cells are strongly correlated with clinical responses to GW506U78.

AB - Purpose: In vitro investigations with arabinosylguanine (ara-G) demonstrated potent cytatoxicity to T-lymphoblastoid cell lines. The goals of the present study were to evaluate GW506U78, a prodrug of ara-G, against human hematologic malignancies and to determine its pharmacokinetics in plasma and cells. Patients and Methods: During o phase I multicenter trial of GW506U78, 26 patients were treated at M.D. Anderson Cancer Center (MDACC). Daily doses between 20 and 60 mg/kg were administered for 5 days. Parallel plasma and cellular pharmacokinetic studies were conducted. Results: Complete (n = 5) or partial remission (n = 5) was achieved in T-cell acute lymphoblastic leukemia (T-ALL), T-lymphoid blast crisis, T-lymphoma, and B- cell chronic lymphocytic leukemia (B-CLL) (n = 13). In contrast, patients with B-ALL, B-lymphoma, acute myelogenous leukemia (AMI), or T-CLL did not respond. Peak plasma concentrations of GW506U78 and ara-G were dose- dependent. The elimination of GW506U78 (half life [t 1/4 ] = 17 minutes) was faster than the elimination of ara-G (t 1/4 = 3.7 hours). Median peak concentrations of ara-GTP were 23, 42, 85, and 93 μmol/L at 20, 30, 40, and 60 mg/kg, respectively. T-lymphoblasts accumulated significantly (P = .0008) higher peak arabinsyl-guanosine triphosphate (ara-GTP) (median, 140 μmol/L; n = 7) compared with other diagnoses (median, 50 μmol/L; n = 9) and normal mononuclear cells (n = 3). The ara-GTP elimination was slow in all diagnoses (median, > 24 hours). Responders accumulated significantly (P = .0005) higher levels of ara-GTP (median, 157 μmol/L) compared with patients who failed to respond (median, 44 μmol/L). Conclusion: GW506U78 is an effective prodrug and a potent agent for hematologic malignancies with major efficacy in T- cell diseases. The pharmacokinetics of ara-GTP in leukemia cells are strongly correlated with clinical responses to GW506U78.

UR - http://www.scopus.com/inward/record.url?scp=0031792644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031792644&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 3607

EP - 3615

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -